Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...
Beijing Beilu Pharmaceutical Co., Ltd invites youto participate in the 2023 World Life Science Conference and Beijing International Life and Health Industry Cross-border ExpoBooth Number: 1B210Exhibit...
Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...
Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...
In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...